Endometrial cancer is the most common gynecologic cancer in the United States, and its
incidence is rising. Although there have been significant recent advances in our …

Purpose A joint American Society of Clinical Oncology, American Society for Radiation
Oncology, and Society of Surgical Oncology panel convened to develop a focused update of …

Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …

Background Vascular endothelial growth factor is a key promoter of angiogenesis and
disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti–vascular …

Background Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared
with tamoxifen, in postmenopausal women with hormone-receptor–positive breast cancer …

OBJECTIVE: To determine indications for the use of postmastectomy radiotherapy (PMRT)
for patients with invasive breast cancer with involved axil-lary lymph nodes or locally …

Background Data are limited regarding the use of poly (adenosine diphosphate [ADP]–
ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed …

Background Suppression of ovarian estrogen production reduces the recurrence of
hormone-receptor–positive early breast cancer in premenopausal women, but its value …

Background Olaparib is a poly (ADP-ribose) polymerase inhibitor and cediranib is an anti-
angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3 …

Purpose To determine whether the addition of paclitaxel to doxorubicin plus cisplatin
improves overall survival (OS) in women with advanced or recurrent endometrial carcinoma …